Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953089 · ClinicalTrials.gov registry record · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase 2 study of Solid Tumors, sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 492
- Enrollment target
- 20
- Study locations
NCT06953089 is a Phase 2 study of Solid Tumors that is actively recruiting participants, run by DualityBio. The registered enrollment target is 492 participants, above the 281-participant average among 125 other Solid Tumors trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT06953089, a Phase 2 study of Solid Tumors, is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 492 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Conditions Studied
Interventions
- DRUG DB-1305/BNT325
- DRUG BNT327
- DRUG DB-1311/BNT324
Study Locations (20)
California
- USA06-0 - Los Angeles
- USA16-0 - Los Angeles
Texas
- USA13-0 - Anderson
- USA12-0 - Houston
Washington
- USA09-0 - Puyallup
- USA07-0 - Spokane
Queensland
- AUS06-0 - Benowa
- AUS04-0 - Birtinya
Colorado
- USA01-0 - Wheat Ridge
Florida
- USA08-0 - Florida City
Georgia
- USA10-0 - Atlanta
Maryland
- USA11-0 - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953089
The ClinicalTrials.gov registry entry for NCT06953089 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 281-participant average among 125 other Solid Tumors trials with a reported enrollment target (75% higher). The listed sponsor is DualityBio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which DB-1305/BNT325 is the first listed.
NCT06953089 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT06953089 about?
NCT06953089 is a clinical study titled "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors". A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
What is the current status of trial NCT06953089?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 492 participants. The study started on 2025-07-18. Estimated completion is 2030-06-30.
What conditions does trial NCT06953089 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06953089?
The interventions under investigation include: DB-1305/BNT325 (DRUG), BNT327 (DRUG), DB-1311/BNT324 (DRUG).
Who is sponsoring clinical trial NCT06953089?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06953089 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RECRUITING · Phase 2
-
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
RECRUITING · Phase 2
-
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
RECRUITING · Phase 2
-
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.